| Alfred M Pascual, DO | |
|
18300 Roscoe Blvd, Northridge, CA 91328 | |
| (818) 885-8500 | |
| Not Available |
| Full Name | Alfred M Pascual |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 40 Years |
| Location | 18300 Roscoe Blvd, Northridge, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336106665 | NPI | - | NPPES |
| 00AX51820 | Medicaid | CA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 20A5182 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Northridge Hospital Medical Center | Northridge, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ridgeline Emergency Physicians Medical Group, Inc. | 0345521613 | 14 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
A recent study finds that the vast majority of Black adolescents have experienced racism, that they experience anticipatory stress about experiencing racism again, and that their racial identity can influence that stress in a variety of ways.
BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.
› Verified 1 days ago
| Entity Name | Ridgeline Emergency Physicians Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972953230 PECOS PAC ID: 0345521613 Enrollment ID: O20161228000227 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
A recent study finds that the vast majority of Black adolescents have experienced racism, that they experience anticipatory stress about experiencing racism again, and that their racial identity can influence that stress in a variety of ways.
BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alfred M Pascual, DO Po Box 12410, Westminster, CA 92685-1241 Ph: (866) 234-5107 | Alfred M Pascual, DO 18300 Roscoe Blvd, Northridge, CA 91328 Ph: (818) 885-8500 |
News Archive
Pancreatic cancer is expected to become the second deadliest cancer in the United States by 2030. It is tough to cure because it is usually not discovered until it has reached an advanced stage. But a new diagnostic test developed by researchers at UC San Diego shows promise for detecting the disease earlier.
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's ixekizumab, an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
A recent study finds that the vast majority of Black adolescents have experienced racism, that they experience anticipatory stress about experiencing racism again, and that their racial identity can influence that stress in a variety of ways.
BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline. BioWa and GSK have amended their existing 2007 arrangement in order to provide GSK with extended access to BioWa's POTELLIGENT Technology platform for the research, development and commercialization of their antibody therapeutics with enhanced antibody-dependent cellular cytotoxicity. The second license agreement provides GSK with access to BioWa's COMPLEGENT Technology for enhancing the complement-dependent cytotoxicity of select GSK therapeutic antibodies.
› Verified 1 days ago
Matthew P Beatty, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Steven L Cole, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Ivan C Rokos, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 | |
Boris Viadamir Lubavin, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 8510 Balboa Blvd, Ste 150, Northridge, CA 91325 Phone: 888-988-2800 | |
Gabriel Henry Campion, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 18300 Roscoe Blvd, Northridge, CA 91325 Phone: 818-885-8500 | |
Shannon M Mcfarland, PA Emergency Medicine Medicare: Medicare Enrolled Practice Location: 18300 Roscoe Blvd, Northridge, CA 91328 Phone: 818-885-8500 |